Logo

Alnylam Licenses RNAi Patent to RNAx

Jan 27, 2004

NEW YORK, Jan. 27 (GenomeWeb News) - Alnylam Pharmaceuticals, through its German affiliate, Ribopharma, has granted a license to its RNAi patent to Ribopharma, the company said today.

 

The patent covers the use of short double-stranded RNAs for RNA interference. RNAx, based in Berlin, will pay an initial and annual licensing fees, as well as royalties on services it provides using the technology.

 

Earlier this month, Alnylam, based in Cambridge, Mass., licensed the patent to Invitrogen, Cell Signaling Technology, and Cenix Bioscience.

 

Breaking News
The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.